Start the conversation
"You almost have to treat early stage biotechs as junior miners."
Michael Robinson, the Radical Technology Profits editor and our in-house tech expert, made that statement to me just the other day, during one of the hour-long talks we seem to have each afternoon.
It was an intriguing statement, but I knew just what he meant. These baby biotechs are volatile investments, and conventional "trailing stop" strategies can end up shaking investors out of what could end up being very lucrative investments. Michael was essentially wondering aloud if it might not be better to set a time limit on these - using that to manage risk, instead of the "trailing stop" approach.
This is premium content for Private Briefing subscribers only.